Navigation Links
Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
Date:10/3/2007

e program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our proprietary enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to their SEPA technology, MacroChem is also evaluating applications for MacroDerm(TM), their patented series of polymers that impede penetration of active ingredients through the skin. The in-licensing of pexiganan represents the first product under the Company's previously stated strategy to seek such opportunities to complement its proprietary products based on its transdermal drug delivery technologies. For more information visit their website, http://www.macrochem.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Genaera Discontinues Lomucin in Cystic Fibrosis Studies
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
3. PM announces a new health care order for India
4. Ramdoss Announces Introduction of RCH-II
5. Britain Announces Third Transfusion Related Mad Cow Case
6. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
7. Tibet Announces the Dalai Lama’s Tour of South Americ
8. NHS announces further Cost cutting Measures
9. Indian PM Announces Of Setting Up India Study Center At Tashkent
10. PowderMed Announces Needle-Less Flu Vaccine
11. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... More than 28,000 students in ... children living with autism will converge upon Penn State to share the latest ... National Autism Conference will be held Aug. 3-6 at the Penn Stater Conference ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... ... Fitness as a sponsor, with its Topricin® Pain Relief and Healing Cream designated ... a firefighter-founded web-based organization that is actively addressing Line of Duty Deaths (LODD) ...
(Date:7/29/2015)... Jacksonville, Fla. (PRWEB) , ... July 29, 2015 , ... ... due to record-setting precipitation levels this spring. And, where there is water, mold is ... and commercial property, offers tips for protecting against water and mold damage. Paul Davis ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... its name in July to Kalamazoo Strength & Conditioning. , The name change ... “reflects the evolution of our training center over the past three years,” according ...
(Date:7/29/2015)... Willingboro, NJ (PRWEB) , ... July 29, 2015 , ... ... Jersey to now offer the Rotation Medical Rotator Cuff System, a new implant to ... “bioinductive” implant is designed to foster natural regeneration of additional tendon tissue, which could ...
Breaking Medicine News(10 mins):Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3
... Reserve University researchers, from the School of Medicine,s Department ... products of lipid peroxidation and some drugs of abuse, ... by a combination of metabolomics and mass isotopomer analysis. ... action of the drug of abuse gamma-hydroxybutyrate, also known ...
... ... looking for an alternative to the high price of dental work in the US, Canada, and ... Vacation is a great choice as a dental tourist destination. , ... (PRWEB) December 4, 2009 -- After being in business for more than ...
... Move a response to pressure from federal regulators to crack ... (HealthDay News) -- The makers of 24 different prescription painkillers ... abuse of these opioid drugs. , The pharmaceutical companies ... officials to find a way to stop the hundreds of ...
... for at-risk patient groups , FRIDAY, Dec. 4 (HealthDay ... central nervous system tumors, carry the risk of late ... analyzed data from 12,795 five-year survivors of the most ... Cancer Survivor Study. , The researchers found that the ...
... shows , FRIDAY, Dec. 4 (HealthDay News) -- Water pipes ... , A new study found that people who smoke tobacco ... puts them at risk for heart disease and nicotine addiction. ... who smoked tobacco using a water pipe and a single ...
... ... ... inventor garnering national attention with an invention proven to help individuals lose weight, prevent ... Saturday’s Technology Fair located at the Civic Center Gallery., , , , , TrekDesk ...
Cached Medicine News:Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Valley Health Invention Making National Splash Showcased at Scottsdale Civic Center Gallery 2
(Date:7/29/2015)... FRANCISCO , July 29, 2015   KaloBios ... antibody company focused on developing innovative therapies to benefit ... focus on oncology, announced today that the U.S. Food ... new drug (IND) application for KB003, an anti-GM-CSF monoclonal ... and that the IND is now active. ...
(Date:7/29/2015)... 2015  Ortho-Clinical Diagnostics, Inc. (OCD) today announced the ... assays address a range of important tests for clinical ... I. The scientific posters will be delivered during the ... be held July 26 - 30 in ... Diagnostics is emerging stronger than ever since becoming a ...
(Date:7/29/2015)... 27, 2015 Research and Markets ( ... "Global Neurostimulation Devices Market 2015" report ... the global neurostimulation devices market to grow at ... The report, Global Neurostimulation Devices Market ... market analysis with inputs from industry experts. The ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3Global Neurostimulation Devices Market 2015-2019 2
... SAN DIEGO and JERUSALEM, May 17, 2012  Ambit Biosciences ... ) ("Teva") today announced the clearance of an Investigational New ... Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor.  ... promising therapeutic potential for this agent, as evidenced by ...
... May 17, 2012 - Atu027, a First ... Activity in Cancer Patients and Possible Biomarker Identified ... of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting ... "Company"), a leading global RNA interference (RNAi) therapeutics company, today ...
Cached Medicine Technology:Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 2Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 3Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 4Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
Medicine Products: